Diabetes Research and Clinical Practice
Volume 87, Issue 3 , Pages 360-365 , March 2010

Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses

  • Helena W. Rodbard

      Affiliations

    • Endocrine and Metabolic Associates, Rockville, MD, USA
    • ,
  • Andrew J. Green

      Affiliations

    • Midwestern Endocrinology, Overland Park, KS, USA
    • ,
  • Kathleen M. Fox

      Affiliations

    • Strategic Healthcare Solutions, LLC, Monkton, MD, USA
    • Corresponding Author InformationCorresponding author at: P.O. Box 543, Monkton, MD 21111, USA. Tel.: +1 443 690 2198; fax: +1 410 357 8018.
    • ,
  • Susan Grandy

      Affiliations

    • AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
    • ,
  • for the SHIELD Study Group

Received 31 July 2009 ,Revised 24 November 2009 ,Accepted 30 November 2009.

References 

  1. Green J, Feinglos M. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int. J. Clin. Pract. 2007;61(Suppl. 154):3–11
  2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005–2012
  3. Charbonnel B. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes. Int. J. Clin. Pract. 2007;61(Suppl. 153):1–2
  4. Gonzalez GL, Manrique CM, Sowers JR. High cardiovascular risk in patients with diabetes and the cardiometabolic syndrome: mandate for statin therapy. J. Cardiometab. Syndr. 2006;1:178–183
  5. Barnett AH. Treating to goal: challenges of current management. Eur. J. Endocrinol. 2004;151(Suppl. 2):T3–T7
  6. Tseng CW, Tierney EF, Gerzoff RB, Dudley RA, Waitzfelder B, Ackermann RT, et al. Race/ethnicity and economic differences in cost-related medication underuse among insured adults with diabetes: the Translating Research Into Action for Diabetes Study. Diabetes Care. 2008;31:261–266
  7. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care. 2004;27:384–391
  8. National Center for Health Statistics, Health, United States, 2008 with Chartbook, Hyattsville, MD, 2009.
  9. American Diabetes Association . Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31:596–615
  10. Bays HE, Bazata DD, Clark NG, Gavin JR, Green AJ, Lewis SJ, et al. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). Biomed. Central Public Health. 2007;7:277
  11. Clark NG, Fox KM, Grandy S for the SHIELD Study Group. Symptoms of diabetes and their association with the risk and presence of diabetes. Diabetes Care. 2007;30:2868–2873
  12. US Census Bureau, Annual Supplement to the Current Population Survey: Census Bureau Resident Population Estimates of the United States, US Census Bureau, Washington, DC, 2003.
  13. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512–1517
  14. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral antihyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J. Clin. Pharm. Ther. 2002;27:213–220
  15. Dezii CM, Kawabata H, Tran. M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med. J. 2002;95:68–71
  16. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid patient population with type 2 diabetes mellitus. Clin. Ther. 2001;23:1311–1320
  17. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet. Med. 2002;19:279–284
  18. Cheong C, Barner JC, Lawson KA, Johnsrud MT. Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin. Ther. 2008;30:1893–1907
  19. Grant RW, Devita NG, Singer DE, Meigs JB, Polypharmacy . medication adherence in patients with type 2 diabetes. Diabetes Care. 2003;26:1408–1412
  20. MacLaughlin EJ, Raehl CL, Treadway AK, Sterling TL, Zoller DP, Bond. CA. Assessing medication adherence in the elderly: which tools to use in clinical practice?. Drugs Aging. 2005;22:231–255

☆ This research was supported by AstraZeneca Pharmaceuticals LP.

PII: S0168-8227(09)00492-6

doi: 10.1016/j.diabres.2009.11.021

Diabetes Research and Clinical Practice
Volume 87, Issue 3 , Pages 360-365 , March 2010

Article Tools

* Image Usage & Resolution